Biopharma Co. Hits Regulatory Hurdle in High-Priority Bird Flu Program

1. Cori Fisher wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
2.  This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company. 
3. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

On June 12, 2026, Traws Pharma, Inc. (TRAW:NASDAQ) announced that its planned test of tivoxavir marboxil (TXM) in a Phase 2a influenza challenge study has been deferred due to a negative review of the program from the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA).

David Pauza, Ph.D., and Chief Science Officer of Traws Pharma, said in the release: "Tivoxavir marboxil demonstrated potent efficacy in three animal models of highly pathogenic avian influenza and a pharmacokinetic profile consistent with its use for bird flu treatment and prevention. The product candidate retains potential for emergency use in a bird flu outbreak and for prevention in high-risk populations. The company has a portfolio of back-up influenza antiviral compounds and is actively advancing candidates with TXM's long-duration pharmacokinetic and antiviral profile, devoid of any mutagenic potential."

In an attempt to reassure investors, Robert Redfield, MD, and Chief Medical Officer for Traws Pharma, said: "Influenza, including bird flu, continues to be a major public health threat in the U.S. and worldwide. While we have had a setback in the development of our lead compound for influenza, the program continues to be a high priority. Influenza treatment and prevention is especially important for vulnerable populations, including elderly and immunocompromised individuals, who are at much greater risk for severe influenza compared to the general population."

Finally, Iain Dukes, MA, D.Phil., and CEO of Traws Pharma, weighed in with future plans. Dukes said, "We remain committed to advancing long-acting influenza antivirals and continue to believe this modality has meaningful potential in seasonal influenza prophylaxis. While the recent regulatory feedback affects the timing of our planned challenge study, it does not change our conviction in the underlying scientific rationale. With our cash runway extending to Q1 2027, we are advancing alternative candidates designed to preserve TXM's pharmacokinetics and efficacy, and exclude potential regulatory concerns."

Traws Pharma Inc. is a clinical-stage biopharma company focused on developing novel therapies that target critical threats to human health via respiratory viral diseases by integrating antiviral drug development, medical intelligence, and regulatory strategy.

Flu Research & Development Programs Lacking

During the 2023-2024 flu season, influenza cost the U.S. roughly US$29 billion and contributed to at least 27,000 adult deaths. While the flu vaccine has proven highly effective, there is little research into pharmaceuticals that could prevent the flu.

In February 2026, Iqvia discussed the global pharma market projection for 2026, noting that total drug usage is expected to surpass four trillion doses daily by 2030. They wrote, "The largest drivers of medicine spending growth through the next five years will continue to be the use in developed markets of innovative therapeutics, especially in oncology, immunology, diabetes, and obesity."

Pharma sector funding fell between 2024 and 2025, according to a March 26, 2026, article for Fierce Biotech by Nick Paul Taylor.  He wrote that pharma funding had fallen from 2024 but noted that, "2025 was still the third-best year of the past decade. Similarly, overall funding was well above the pre-pandemic norm and only topped by 2020, 2021, and 2024."

BCG talked about trends biopharma companies need to be aware of in 2026 in order to stay competitive, saying, "Near term, companies need to continue to innovate to decrease the complexity and cost of these therapies, and governments can find ways to incentivize and pay for them. The longer-term challenge for companies is to factor operational and economic considerations into R&D decision making earlier, ensuring that trial designs match real-world usage, indication sequences match opportunity, and endpoints enable market access."

Analyst Downgrades Stock Rating

Brandon Folkes of H.C. Wainwright & Co. downgraded Traws Pharma's rating from "Buy" to "Neutral" on June 18, 2026, after the company's announcement.

Folkes wrote: "Despite the falloff in the COVID market opportunity, we felt the potential for the influenza program was interesting enough, that despite being early, justified our continued Buy rating on the stock. Following Friday's announcement, we no longer have sufficient conviction that tivoxavir marboxil (TXM) can serve as a near-term value driver for investors." 

Catalysts Delayed but Still Ahead

Folkes noted in his research report that, "TRAW did note in May that it was initiating a hantavirus/Ebola antiviral program which could add longer-term optionality to the pipeline, particularly if the company can leverage its antiviral platform into outbreak-driven indications with limited treatment options."

Traws Pharma is hopeful that it can resume the TXM study by early 2027.

Ownership & Share Information¹

Traws Pharma Inc. has a market cap of US$12.10 million, with 15.15 million shares outstanding. The company's 52-week range is US$0.64-US$3.27.

Institutions own 44.43%, while Management & Insiders own 5.50%. The remaining 50.07% of shares are Retail.